(Q43205096)

16 November 2017

Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin (English)

1 reference

16 November 2017

1 reference

Pan HY

1

1 reference

16 November 2017

Triscari J

2

1 reference

16 November 2017

DeVault AR

3

1 reference

16 November 2017

Smith SA

4

1 reference

16 November 2017

Wang-Iverson D

5

1 reference

16 November 2017

Swanson BN

6

1 reference

16 November 2017

Willard DA

7

1 reference

16 November 2017

language of work or name

English

0 references

publication date

1 June 1991

1 reference

British Journal of Clinical Pharmacology

16 November 2017

1 reference

16 November 2017

31

1 reference

16 November 2017

6

1 reference

16 November 2017

665-670

1 reference

Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol.

16 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Propranolol interactions with diazepam, lorazepam, and alprazolam.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Pharmacokinetic Drug Interactions with Propranolol

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Effects of beta-adrenoceptor antagonists on the pharmacokinetics of lignocaine

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

The influence of captopril, the nitrates and propranolol on apparent liver blood flow

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

HMG-CoA reductase inhibitors for treatment of hypercholesterolemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Adverse reactions and interactions with beta-adrenoceptor blocking drugs

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Lovastatin and other HMG-CoA reductase inhibitors

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Determination of lovastatin acid in serum by gas chromatography/mass spectrometry

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Lidocaine elimination: effects of metoprolol and of propranolol.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1368577

Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism

15 August 2018

1 reference

12 December 2020

The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects

1 reference

12 December 2020

The physiological disposition of lovastatin

1 reference

12 December 2020

Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry

1 reference

12 December 2020

Lovastatin: a new cholesterol-lowering agent

1 reference

12 December 2020

Effects of metoprolol and propranolol on theophylline elimination

1 reference

12 December 2020

10.1111/J.1365-2125.1991.TB05590.X

Identifiers

DOI

1 reference

16 November 2017

1 reference

16 November 2017

PubMed publication ID

1907839

1 reference